Cargando…

Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials

INTRODUCTION: Conventional lipid-lowering agents, including statins, ezetimibe, fibrates, bile acid sequestrants, nicotinic acid, bempedoic acid and Omega-3, are essential to the management of dyslipidaemia. However, these agents have been shown to increase the level of plasma proprotein convertase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jichang, Huang, Tianze, Xu, Ran, Wang, Xue, Yang, Yutong, Li, Long, Zhang, Xiao, Zhang, Yinhang, Yang, Renjie, Wang, Jie, Yang, Hai, Ma, Yan, Yang, Bin, Wang, Tao, Jiao, Liqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462109/ https://www.ncbi.nlm.nih.gov/pubmed/36691198 http://dx.doi.org/10.1136/bmjopen-2022-061884

Ejemplares similares

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

NF-κB and its crosstalk with endoplasmic reticulum stress in atherosclerosis
por: Li, Wenjing, et al.
Publicado: (2022)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
por: Zheng, Jianan, et al.
Publicado: (2023)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

Treatment strategies for asymptomatic carotid artery stenosis in the era of lipid-lowering drugs: protocol for a systematic review and network meta-analysis
por: Bai, Xuesong, et al.
Publicado: (2020)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

PCSK9 Gene E670G Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis of 5,484 Subjects
por: Li, Yan-yan, et al.
Publicado: (2020)

Comparison of effectiveness and safety of high-power vs. conventional-power radiofrequency ablation for treatment of atrial fibrillation
por: Cui, Penghui, et al.
Publicado: (2022)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: a protocol for systematic review and meta-analysis
por: Ye, Xuejiao, et al.
Publicado: (2023)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Plasma Homocysteine Level Is Independently Associated With Conventional Atherogenic Lipid Profile and Remnant Cholesterol in Adults
por: Zhou, Liyuan, et al.
Publicado: (2022)

Visceral Adiposity and Risk of Stroke: A Mendelian Randomization Study
por: Xu, Ran, et al.
Publicado: (2022)

Risk Factors of New Cerebral Infarctions After Endovascular Treatment for Basilar Artery Stenosis Based on High-Resolution Magnetic Resonance Imaging
por: Luo, Jichang, et al.
Publicado: (2021)

Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial
por: Xia, Jiachun, et al.
Publicado: (2022)

SUN-574 A1AT: Novel Inhibitor of Active PCSK9
por: Melendez, Quantil, et al.
Publicado: (2020)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

Extracranial-intracranial bypass surgery for occlusive atherosclerotic disease of the anterior cerebral circulation: protocol for a systematic review and meta-analysis
por: Bai, Xuesong, et al.
Publicado: (2020)

Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
por: Wang, Yanan, et al.
Publicado: (2023)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
por: Iwabuchi, Masayasu
Publicado: (2020)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study
por: Cacciottolo, Paul J, et al.
Publicado: (2021)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
por: Khoshnejad, Makan, et al.
Publicado: (2019)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q5bo9e016hgf3ujlmsul44a663